Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

被引：0
|
作者：
Reece, Donna E.
Masih-Khan, Esther [1 ]
Khan, Arooj [1 ]
Dean, Saima [1 ]
Fung, Sharon [2 ]
Anglin, Peter [4 ]
Chen, Christine
Kukreti, Vishal
Mikhael, Joseph R. [3 ]
Trudel, Suzanne [5 ]
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Princess Margaret Hosp, Dept Biostat, Toronto, ON M4X 1K9, Canada
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Southlake Reg Canc Ctr, Newmarket, ON, Canada
[5] Princess Margaret Hosp, McLaughlin Ctr Mol Med, Toronto, ON M4X 1K9, Canada
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1260 / 1260
页数：1
相关论文
共 50 条
  • [1] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Dean, Saima
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BLOOD, 2009, 114 (22) : 744 - 744
  • [2] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Truidel, Suzanne
    BLOOD, 2008, 112 (11) : 607 - 607
  • [3] Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Jimenez-Zepeda, Victor H.
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) : 46 - 54
  • [4] Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
    Reece, Donna E.
    Rodriguez, Giovanni Piza
    Chen, Christine
    Trudel, Suzanne
    Kukreti, Vishal
    Mikhael, Joseph
    Pantoja, Mariela
    Xu, Wei
    Stewart, A. Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4777 - 4783
  • [5] A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma.
    Reece, Donna E.
    Piza, Giovanni
    Trudel, Suzanne
    Pantoja, Manela
    Chen, Christine
    Mikhael, Joseph R.
    Kukreti, Vishal
    Stewart, Keith
    BLOOD, 2006, 108 (11) : 1009A - 1009A
  • [6] Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
    Reece, D.
    Masih-Khan, E.
    Anglin, P.
    Chen, C.
    Kukreti, V.
    Khan, A.
    Mikhael, J.
    Trudel, S.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S53 - S53
  • [7] A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
    Palumbo, Antonio
    Larocca, Alessandra
    Carella, Angelo Michele
    Rossi, Davide
    Montefusco, Vittorio
    Ferrari, Samantha
    Santagostino, Alberto
    Guglielmelli, Tommasina
    Galli, Monica
    Capaldi, Antonio
    Giuliani, Nicola
    La Verde, Giacinto
    Omede, Paola
    Baldi, Ileana
    Boccadoro, Mario
    Corradini, Paolo
    BLOOD, 2011, 118 (21) : 289 - 290
  • [8] A phase I-II trial of bortezomib (Veleade) (Vc) and oral cyclophosphamide (CY) plus prednisone (P) for relapsed/refractory multiple myeloma (MM).
    Reece, DE
    Piza, G
    Trudel, S
    Chen, C
    Mikhael, JR
    Stewart, AK
    BLOOD, 2005, 106 (11) : 718A - 718A
  • [9] Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study
    Zelis, N.
    Devos, T.
    Dierickx, D.
    Janssens, A.
    Raddoux, J.
    Verhoef, G.
    Delforge, M.
    ACTA CLINICA BELGICA, 2014, 69 (02) : 98 - 103
  • [10] A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma.
    Richardson, P
    Schlossman, R
    Munshi, N
    Avigan, D
    Jagannath, S
    Alsina, M
    Doss, D
    McKenney, M
    Hande, K
    Farrell, M
    Gorelik, S
    Colson, K
    Warren, D
    Lunde, L
    Michelle, R
    Cole, G
    Mitsiades, C
    Hideshima, T
    Myers, T
    Knight, R
    Anderson, K
    BLOOD, 2005, 106 (11) : 110A - 111A
12345